206 related articles for article (PubMed ID: 36588692)
1. ASK120067 potently suppresses B-cell or T-cell malignancies
Song P; Bai G; Chan S; Zhang T; Tong L; Su Y; Shen Y; Chen Y; Liu Y; Lai M; Ning Y; Tang H; Fang Y; Chen Y; Ding K; Ding J; Xie H
Front Pharmacol; 2022; 13():1071114. PubMed ID: 36588692
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Cx43 Gap Junction Intercellular Communication by Bruton's Tyrosine Kinase and Interleukin-2-Inducible T-Cell Kinase.
Basu I; Li H; Trease AJ; Sorgen PL
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189407
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.
Guo W; Liu R; Ono Y; Ma AH; Martinez A; Sanchez E; Wang Y; Huang W; Mazloom A; Li J; Ning J; Maverakis E; Lam KS; Kung HJ
Mol Pharmacol; 2012 Nov; 82(5):938-47. PubMed ID: 22899868
[TBL] [Abstract][Full Text] [Related]
5. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
6. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
7. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
Aalipour A; Advani RH
Ther Adv Hematol; 2014 Aug; 5(4):121-33. PubMed ID: 25360238
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Muqbil I; Chaker M; Aboukameel A; Mohammad RM; Azmi AS; Ramchandren R
Heliyon; 2019 Aug; 5(8):e02290. PubMed ID: 31508518
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
12. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
13. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
14. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
15. A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk.
Douhan J; Miyashiro JS; Zhou X; Cole DC; Wu PW; Collins M; Dunussi-Joannopoulos K
Assay Drug Dev Technol; 2007 Dec; 5(6):751-8. PubMed ID: 18181691
[TBL] [Abstract][Full Text] [Related]
16. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
[TBL] [Abstract][Full Text] [Related]
17. Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.
Kueffer LE; Joseph RE; Andreotti AH
Front Cell Dev Biol; 2021; 9():655489. PubMed ID: 34249912
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
[TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
Su R; Diao Y; Sha W; Dou D; Yu Z; Leng L; Zhao Z; Chen Z; Li H; Xu Y
Bioorg Chem; 2022 Sep; 126():105860. PubMed ID: 35661525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
